NASDAQ:LMNX - Luminex Stock Price, Forecast & News

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

Luminex announced a quarterly dividend on Tuesday, February 18th. Investors of record on Thursday, March 19th will be paid a dividend of $0.09 per share on Thursday, April 9th. This represents a $0.36 annualized dividend and a yield of 1.53%. The ex-dividend date of this dividend is Wednesday, March 18th. View Luminex's Dividend History.

Luminex Co. (NASDAQ:LMNX) announced its quarterly earnings data on Monday, February, 10th. The medical instruments supplier reported $0.07 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.08. The medical instruments supplier earned $90.50 million during the quarter, compared to the consensus estimate of $90.27 million. Luminex had a negative net margin of 1.18% and a negative return on equity of 2.03%. The company's quarterly revenue was up 11.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.04 EPS. View Luminex's Earnings History.

Luminex is scheduled to release their next quarterly earnings announcement on Monday, May 4th 2020. View Earnings Estimates for Luminex.

Luminex updated its first quarter 2020 After-Hours earnings guidance on Monday, February, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $82-84 million, compared to the consensus revenue estimate of $87.74 million.

3 brokerages have issued 12 month price targets for Luminex's stock. Their forecasts range from $21.00 to $32.00. On average, they expect Luminex's share price to reach $26.50 in the next twelve months. This suggests a possible upside of 12.7% from the stock's current price. View Analyst Price Targets for Luminex.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Luminex.

News articles about LMNX stock have been trending negative this week, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Luminex earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave news headlines about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Luminex.

Luminex saw a increase in short interest during the month of February. As of February 14th, there was short interest totalling 1,400,000 shares, an increase of 5.3% from the January 30th total of 1,330,000 shares. Based on an average trading volume of 268,300 shares, the days-to-cover ratio is currently 5.2 days. Approximately 3.4% of the company's shares are short sold. View Luminex's Current Options Chain.

Some companies that are related to Luminex include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), Charles River Laboratories Intl. (CRL), BIO-TECHNE (TECH), Bruker (BRKR), Cambrex (CBM), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Luminex investors own include AbbVie (ABBV), Pfizer (PFE), Baidu (BIDU), Micron Technology (MU), Verizon Communications (VZ), Gilead Sciences (GILD), Alphabet (GOOG), Nektar Therapeutics (NKTR), Starbucks (SBUX) and Canopy Growth (CGC).

Luminex's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (5.10%), State Street Corp (2.87%), Investment Management of Virginia LLC (2.05%), Geode Capital Management LLC (1.33%), Bank of New York Mellon Corp (1.33%) and Bank of America Corp DE (0.96%). Company insiders that own Luminex stock include Charles J Collins, Eric Shapiro, G Walter Loewenbaum II, Nachum Shamir and Todd C Bennett. View Institutional Ownership Trends for Luminex.

LMNX stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, THB Asset Management, Martingale Asset Management L P, Russell Investments Group Ltd., AQR Capital Management LLC, Skandinaviska Enskilda Banken AB publ , Bessemer Group Inc. and Bank of New York Mellon Corp. View Insider Buying and Selling for Luminex.

LMNX stock was purchased by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, California Public Employees Retirement System, Goldman Sachs Group Inc., Eos Focused Equity Management L.P., Aviva PLC, State Street Corp, Bank of Montreal Can and Renaissance Technologies LLC. Company insiders that have bought Luminex stock in the last two years include G Walter Loewenbaum II and Nachum Shamir. View Insider Buying and Selling for Luminex.

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of LMNX stock can currently be purchased for approximately $23.51.

Luminex has a market capitalization of $1.06 billion and generates $334.64 million in revenue each year. The medical instruments supplier earns $-3,840,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Luminex employs 988 workers across the globe.View Additional Information About Luminex.

The official website for Luminex is http://www.luminexcorp.com/.

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]